English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In 1974, Peter Doherty and Rolf Zinkernagel published a landmark article in Nature [ 1 ] that described the ability of lymphocytic choriomeningitis virus (LCMV)-specific cytotoxic T cells to lyse LCMV-infected, 51 Cr-labeled target cells if the target cells shared class I major histocompatibility complex (MHC) molecules with these T cells. Surprisingly, infected and labeled target cells with disparate class I MHC molecules were not lysed. This phenomenon, which came to be known as “MHC restriction,” was a major advance in our understanding of the way in which T cells recognize antigen and was ultimately the basis for the awarding of the 1996 Nobel Prize in Physiology or Medicine to Peter Doherty and Rolf Zinkernagel. Readers interested in more information on Dr. Doherty or on MHC restriction are referred to the relevant pages of the Nobel Prize website [ 2 ].

Peter Doherty, Nobel Laureate: Questions and Reflections Concerning MHC Restriction and other Fruits of a Life of Biomedical Erudition